China: China's Recent Development On Granting Biological Sequence Claims

Last Updated: 9 January 2018
Article by Tao Jiang

Life sciences and biotechnology are widely regarded as one of the most promising frontier technologies for the coming decades. Patent protection is at the core of the business for biotechnology companies, and for them, it is also crucial to understand that there exist strong differences amongst jurisdictions concerning what is considered as patentable subject matter, what disclosure is required, and what claim breath is allowed.

One distinctive feature in biotechnology is to define claims by biological sequences (such as nucleotide sequences, amino acid sequences). In China, however, whether these claims are supported in view of examples provided in the description is a prominent issue. A recent case from Supreme People's Court may shed some lights on the Chinese examination inquiry. This short article discussed the case, as well as Chinese practice.

I. Examination of Biological Sequence Claims in China Has Been Strict

Chinese Patent Law Article 26 (4) prescribes that claims shall be supported by the description and shall define the extent of the patent protection sought for in a clear and concise manner.

With respect to the claim support, Chinese examination and judicial practice impose strict criteria on biological sequence claims, i.e., generally allowing claims that encompass only specifically examples in the description. The underlined rationale is attributed to the assumed low predictability of biotechnology inventions, in other words, technical effects of the claimed inventions are not predictable if they are not confirmed by experimental data. Accordingly, one person skilled in the art would not be able to predict whether all variants within the claim scope would have the same function if the relevant examples are not provided in the description.

In view of the above, the allowed breath of a claim is strictly limited by specific examples in China. Had such patent applications been granted, they might be difficult to enforce as competitors may design around by replacing a few irrelevant nucleotides or amino acids. This practice strongly discourages inventions to be filed in China.

We brief below a retrial case to introduce the latest progress on examination inquiry relating to biological sequence claims.means" under Article 44(1).

II. Supreme People's Court (SPC) Case Opened a Bit for Biological Sequence Claims

On April 24, 2017, SPC issued "the top 10 intellectual property cases of Chinese court in 2016." Among them, there is an invention patent invalidation dispute between the Patent Reexamination Board (PRB) of SIPO, Novozymes AS, and Jiangsu Boli Biological Products Co. Ltd1.

In the retrial judgment, SPC elaborated on how to determine whether the biological sequence claims are supported by the description, and discussed the criteria of granting the patent right for such inventions.

Claims and Focus of Case

Novozymes' Chinese invention patent (CN98813338.5) relates to a thermostable glucoamylase that was isolated, purified and characterized from a strain of Talaromyces emersonii CBS 793.97. Compared with the prior art glucoamylases, the isolated glucoamylase has a very high thermal stability. Therefore, the claimed thermostable glucoamylase is suitable for starch conversion (e.g., for producing glucose from starch), and for use in various processes, in particular the saccharification step in starch convention processes.

During the patent invalidation proceeding,2 the granted claims were amended by the patentee, and the isolated enzyme was defined by the way of (i) "function plus comprising"; (ii) "function plus homology"; (iii) "function plus homology plus source"; and (iv) "function plus comprising plus source" respectively.3

One issue was focused on in the case is whether the claims covering the enzymes are supported by the description. In fact, Example 2 shows that an enzyme having SEQ ID NO: 7 has the desired activity and function, and Examples 8, 9, 11 and 12 show that the polypeptides having SEQ ID NO: 34 also have the same properties. There are three (3) different amino acids between SEQ ID NO: 7 and SEQ ID NO: 34, i.e. SEQ ID NO: 34 is over 99% homologous (1% equivalent to 6 amino acids) to SEQ ID NO: 7.

In other words, the focus becomes: given the fact that the enzyme with SEQ ID NO: 7 and its variant with SEQ ID NO: 34 have the desired activity and function which are confirmed by the experimental data, is it allowable to extend the protection scope of claims to other variants of the enzyme? What kind of manner could be permitted to generalize its variants in the claims?

Claims Defined by"Function Plus Comprising"

This claim definition is typical to define biological sequences, and amended claims 1 and 12 of the patent in dispute are drafted in this manner. Amended claim 1 reads as: An isolated enzyme with glucoamylase activity comprising the full-length sequence shown in SEQ ID NO: 7.

Rejected, Chinese Patent Office, PRB and Courts all agreed upon the unmalleability of this claim definition. In this case, PRB, the first instance court4 and the second instance court5 still took the strict criteria, and concluded that claims 1 and 12, as amended, are not supported by the description because the "comprising" is open-ended, which encompasses numerous sequences possibly having any number and any type of amino acid added at one or both ends of the sequence. As a result, one person skilled in the art would not be able to predict whether all sequences within the claim scope would have the glucoamylase activity, and therefore, claims 1 and 12 are not supported by the description.

Unfortunately, the support issue for claims 1 and 12 was not raised in the retrial procedure, and SPC did not provide their thoughts on this.

Claims Defined by "Function Plus homology"

This claim definition is also typical to define biological sequences, and amended claim 6 of the patent in dispute is drafted in this manner. Amended claim 6 reads as: An isolated enzyme with glucoamylase activity, wherein the homologous enzyme is at least 99% with the full-length sequence shown in SEQ ID NO: 7, and having a pI below 3.5 determined by isoelectrical focusing.

Also rejected, Chinese Patent Office, PRB and Courts all agreed upon the unallowability of this claim definition. In this case, PRB, the first instance court and the second instance court still took the strict criteria, and concluded that claim 6 is not supported by the description, because the claimed enzymes encompass a large number of amino acid sequences. Other than the enzyme having SEQ ID NO: 7 and its variant having SEQ ID NO: 34, one person skilled in the art would not be able to predict whether other homologous sequences also have the glucoamylase activity, and therefore claim 6 is not supported by the description.

Unfortunately, the support issue for claim 6 was not raised in the retrial procedure, and SPC did not provide their thoughts on this.

Claims Defined by "Function Plus Homology Plus Source"

This claim definition is not typical to define biological sequences, and there are no criteria for reference according to the previous examination and trial practice. Amended claims 10 and 11 of the patent in dispute are drafted in this manner. Based on the claim 6, amended claim 10 further defined the enzyme is derived from a strain of the filamentous fungus T. emersonii.

In this case, the different criteria were taken by PRB, the first instance court and the second instance court, and the different conclusions were drawn. After the trial, SPC affirmed the decision from PRB and reasoned that in addition to the homologous character, dependent claims 10 and 11 further define the enzyme species source, which significantly limits the scope of claims. One person skilled in the art would understand species being the basic unit of taxonomy which represents a high degree of similarity to each other, and therefore there would exist only very few variant sequences with very high homology. Together with other limitations defined in claim 6, SPC overturned the decisions from lower courts and concluded claims 10 and 11, as amended, are supported.

Claims Defined by "Function Plus Comprising Plus Source"

This claim definition is not typical to define biological sequences, and there are no criteria for reference according to the previous examination and trial practice either. Amended claims 13 and 14 of the patent in dispute are drafted in this manner. In this case, the different criteria were taken by PRB, the first instance court and the second instance court, and the different conclusions were drawn by them. After the trial, SPC affirmed the decision from PRB and reasoned that although the term "comprising" is used, the functional character for having the glucoamylase activity as well as the enzyme species source are also recited. For the person skilled in the art, only very few DNA sequences comprising the sequence (a) or (b) could be obtained from the T.emersonii strain. Accordingly, SPC concluded that the technical solutions refer to claim 12 (a) and (b) in the claims 13 and 14 are supported by the description.

III. Our Practice Tips Relating to Reasonable Protection for Biological Sequence Inventions

Article 26 (4) of the Patent Law is intended to provide the inventor a reasonable protection commensurate in scope with his contribution to the art. This article is basically the same as the PCT which prescribes claims shall be fully supported by the description. Permission to generalize a biological sequence claim reasonably not only meets the legislative intent of Article 26 (4), but also promotes the technological innovation and development in the biotechnology field.

New Trends for Biological Sequence Claims

During the retrial procedure of the above-discussed case, SPC denied the strict criteria taken by lower courts, and articulated judgment rules and granting criteria for the biological sequence claims. That is the claims defined in the homology plus source and function manner are supported by the description, which is instructive for the drafting, examination and trial for the biological sequence related patent applications.

Accordingly, the protection scope is still limited for the applicants and patentees of the biotechnology field, but it has shown that the criteria for examination and trial of the biological sequence claims in China have begun to become more rational.

Strategies for drafting the Biological Sequence Related Invention

From the above case, it can be seen that the examination and trial criteria for the biological sequence claims in China are still rather strict.

Accordingly, in order to get the more reasonable protection scope, the applicants should draft the claims using as many as possible defined manners. In addition to the above-mentioned four manners, "the combination of the terms 'substitution, deletion or addition' plus functions" and "the combination of the terms 'hybridize under stringent conditions' plus functions" could be taken for claim drafting Furthermore, if a gene, polypeptide or protein could not be described by the above-mentioned manners, the physiochemical properties of the polypeptide or protein and the process for processing the gene, polypeptide or protein could be used by the applicants to draft the claims too.

As we all know, biotechnology is an experimental science, and it is unpredictable for its experimental results in some cases. Therefore, for the person skilled in the art, it is very helpful to describe the background art (such as the gene homologous evolutions, the research and development of the related variants, etc.) in the description in detail. Furthermore, in order to get relatively broad protection scope, at the time of drafting the patent applications related to the biological sequences, as many as possible actual examples should be provided in the description to describe the variants' functions and effects, so that the reasonable expectation for the variants could be made by the examiner based on these experimental data and the gene homologous evolutions between different strains or species.

In addition, in order to support the claims sufficiently, it is better to describe the origin of the biological sequences, the technical means for getting them, and their functions and technical effects when drafting the patent application documents. Especially, it is necessary to describe the relationship between the biological sequences and their functions as much as possible, for example, introducing and verifying the functional and structural domains for the biological sequences in the examples, so that the examiner would understand the whole invention and creation, the key sections for the sequence, and the important functions for the variants better in this way, which will be helpful to acquire reasonable protection scope.

In summary, the retrial judgment made by SPC shows the possibility that biological sequence claims are reasonably protected in China. The applicants should pay more attention when drafting the patent application documents, describe the relationship between the biological sequences and their functions, provide enough examples to describe the variants' functions and effects, and draft the claims using as many as possible defined manners, so that the reasonable protection scope could be granted.

Footnotes

1. Decision No. 85: Supreme People's Court [2016] Retrial Judgment

2. Examination Decision on Request for Invalidation No. 17956

3. Wherein, the "function" means having the glucoamylase activity, the "comprising" means the claim is an open-ended mode, the "homology" means the homologous enzyme of at least 99% with the full-length sequence shown in SEQ ID NO: 7, and the "source" means the enzyme is derived from a strain of the filamentous fungus T. emersonii.

4. Decision No. 2721: Beijing First Intermediate People's Court [2012]

5. Decision No. 3524: Beijing Higher People's court [2014]

Originally published June 2017

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions